EWTX logo

EWTX Edgewise Therapeutics, Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$39.91
-1.26 (-3.07%)

Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully con…

Market Cap: $4.29Bwww.edgewisetx.com

Price

No data yet.

Social Signal Score

50
5d
60
2 mentions
—
30d
43
3 mentions
—
60d
45
4 mentions
—
90d
53
8 mentions
—
rss: 4 · news: 4

Analyst Ratings

11 analysts
Buyconsensus
Strong Buy 0Buy 9Hold 2Sell 0Strong Sell 0
Avg price target$55.33+38.7%
Low $36Median $52High $85
Current Consensus

Revenue

$0.00
$0.00
Mar 2020Sep 2026

Analyst Estimates

FY2025
$-1.60
$-1.65–$-1.57
9 analysts
FY2026
$9.08
$8.92–$9.26
8 analysts
FY2027
$-1.97-122% YoY
$-2.73–$-1.29
11 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Kevin Koch
Sector
Healthcare
Industry
Biotechnology
Employees
133
Beta
0.28
Country
US
Piotroski score
3 / 9 (Weak)
Altman Z-score
21.14
www.edgewisetx.com